<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="In the past two decades, the world has faced several" exact="infectious disease" post="outbreaks. Ebola, Influenza A (H1N1), SARS, MERS, and Zika"/>
 <result pre="the past two decades, the world has faced several infectious" exact="disease" post="outbreaks. Ebola, Influenza A (H1N1), SARS, MERS, and Zika"/>
 <result pre="decades, the world has faced several infectious disease outbreaks. Ebola," exact="Influenza A (H1N1)," post="SARS, MERS, and Zika virus have had a massive"/>
 <result pre="Europe and America correspond about 40% and 30% of the" exact="total" post="reported cases respectively. At this moment only few Asian"/>
 <result pre="have controlled the disease, but a second wave of new" exact="infections" post="is expected. Predicting inhibitor and target to the COVID-19"/>
 <result pre="In the past century, the world has faced five pandemic" exact="respiratory" post="diseases caused by different subtypes of influenza virus and"/>
 <result pre="born from family of coronavirus, two regional epidemics are severe" exact="acute" post="respiratory syndrome (SARS) and middle east respiratory syndrome (MERS)"/>
 <result pre="from family of coronavirus, two regional epidemics are severe acute" exact="respiratory" post="syndrome (SARS) and middle east respiratory syndrome (MERS) in"/>
 <result pre="family of coronavirus, two regional epidemics are severe acute respiratory" exact="syndrome" post="(SARS) and middle east respiratory syndrome (MERS) in 2001"/>
 <result pre="epidemics are severe acute respiratory syndrome (SARS) and middle east" exact="respiratory" post="syndrome (MERS) in 2001 to 2003 and 2012 to"/>
 <result pre="are severe acute respiratory syndrome (SARS) and middle east respiratory" exact="syndrome" post="(MERS) in 2001 to 2003 and 2012 to 2015,"/>
 <result pre="Desease Control &amp;amp; Prevention, 2005; World Health Organization. Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV), 2019). Coronavirus is a family of"/>
 <result pre="Control &amp;amp; Prevention, 2005; World Health Organization. Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV), 2019). Coronavirus is a family of the"/>
 <result pre="and can cause illness such as the common cold, severe" exact="acute" post="respiratory syndrome (SARS) and the Middle East respiratory syndrome"/>
 <result pre="can cause illness such as the common cold, severe acute" exact="respiratory" post="syndrome (SARS) and the Middle East respiratory syndrome (MERS)"/>
 <result pre="cause illness such as the common cold, severe acute respiratory" exact="syndrome" post="(SARS) and the Middle East respiratory syndrome (MERS) (Amanat"/>
 <result pre="cold, severe acute respiratory syndrome (SARS) and the Middle East" exact="respiratory" post="syndrome (MERS) (Amanat &amp;amp; Krammer, 2020). In 2019, a"/>
 <result pre="severe acute respiratory syndrome (SARS) and the Middle East respiratory" exact="syndrome" post="(MERS) (Amanat &amp;amp; Krammer, 2020). In 2019, a new"/>
 <result pre="2019, a new virus identified in china namely novel coronavirus" exact="disease" post="2019 (COVID-19). On 11 March 2020, the World Health"/>
 <result pre="the World Health Organization characterized the COVID-19 as a pandemic" exact="disease" post="(WHO Director-General â€˜s remarks at the media briefing on"/>
 <result pre="far, existing drugs could not be alleviated the disease. The" exact="disease" post="symptoms are fever, cough, sore throat, runny nose and"/>
 <result pre="the disease. The disease symptoms are fever, cough, sore throat," exact="runny nose" post="and difficulty breathing. The china international exchange and promotive"/>
 <result pre="those responsible for the common cold. It is a contagious" exact="viral infection" post="that can be spread through inhalation or ingestion of"/>
 <result pre="responsible for the common cold. It is a contagious viral" exact="infection" post="that can be spread through inhalation or ingestion of"/>
 <result pre="infection that can be spread through inhalation or ingestion of" exact="viral" post="droplets as a result coughing and sneezing and touching"/>
 <result pre="a result coughing and sneezing and touching infected surface are" exact="primary" post="sources of infection. The coronavirus genome is comprised of"/>
 <result pre="turn them into virus factories. The N protein coats the" exact="viral" post="RNA genome which plays a vital role in its"/>
 <result pre="sub-genomic RNAs in MHV and IBV virions and process the" exact="viral" post="replication and transcription. This is one of the important"/>
 <result pre="of N-protein and single positive RNA strand which can stop" exact="viral" post="replication and transcription. Sarma et al. (2020) reported that"/>
 <result pre="signal peptide (SP); transmembrane domain (TM) are shown B) The" exact="viral" post="surface proteins, spike, envelope and membrane, are embedded in"/>
 <result pre="membrane, are embedded in a lipid bilayer. The single-stranded positive-sense" exact="viral" post="RNA is associated with the nucleocapsid protein. The M-protein"/>
 <result pre="the nucleocapsid protein. The M-protein is most abundant in the" exact="viral" post="surface and it is believed to be the central"/>
 <result pre="to the host cell surface receptors and fusion between the" exact="viral" post="and host cell membranes to facilitate viral entry into"/>
 <result pre="fusion between the viral and host cell membranes to facilitate" exact="viral" post="entry into the host cell (Kirchdoerfer et al., 2016)."/>
 <result pre="not required for replication, but appears to be important for" exact="infection" post="of the natural host-cell (Lissenberg et al., 2005). State-of-the-art"/>
 <result pre="which are associated to cell recognition and the fusion of" exact="viral" post="and cellular membranes respectively. The latter process occurs through"/>
 <result pre="protein conformational changes that remain still uncharacterized. The mechanism of" exact="viral" post="entry and replication and RNA packing in the human"/>
 <result pre="way this protocol could device a treatment to block the" exact="viral" post="entry. Typically, human cell ingests the virus in a"/>
 <result pre="opens to release virus to the cytoplasm, and uncoating of" exact="viral" post="nucleocapsid (N) is started via proteasomes which typically can"/>
 <result pre="then it is expected the fusion at low pH between" exact="viral" post="and host target membranes via S2 subunit. Finally, the"/>
 <result pre="viral and host target membranes via S2 subunit. Finally, the" exact="viral" post="genetic material a single stranded RNA is fully released"/>
 <result pre="so-called replication/transcription complex (RTC). Such complex is encoded in the" exact="viral" post="genome and it is made of non-structural proteins (nsp)."/>
 <result pre="which subsequently serve as templates in generating addition full-length genomes." exact="Structural" post="viral proteins, M, S and E are synthesized in"/>
 <result pre="subsequently serve as templates in generating addition full-length genomes. Structural" exact="viral" post="proteins, M, S and E are synthesized in the"/>
 <result pre="endoplasmic reticulum (ER) (Figure 2), and transfer to endoplasmic reticulum-Golgi" exact="intermediate" post="compartment (ERGIC) (Masters, 2006; Song et al., 2004). Also,"/>
 <result pre="can infect other cells. In the meantime, the stress of" exact="viral" post="production on the endoplasmic reticulum eventually leads to cell"/>
 <result pre="The schematic diagram of the mechanism of COVID-19 entry and" exact="viral" post="replication and viral RNA packing in the human cell."/>
 <result pre="of the mechanism of COVID-19 entry and viral replication and" exact="viral" post="RNA packing in the human cell. Figure 3. Three-dimensional"/>
 <result pre="450 and 750 KD respectively, these polyproteins are required for" exact="viral" post="replication and transcription (Wu et al., 2020; Zhou et"/>
 <result pre="4. E-Protein ion channel activity The COVID-19 E-protein is a" exact="short" post="and integral membrane protein that contains 76-109 amino acids,"/>
 <result pre="consist of 35 Î±-helices and 40 loops. The protein has" exact="short" post="hydrophilic amino terminus consisting of 7â€&quot;12 amino acids, followed"/>
 <result pre="it plays a significant role in the assembly of the" exact="viral" post="genome. This protein is involved in several aspects of"/>
 <result pre="the extracellular membrane could disrupt the ion-conductivity and the normal" exact="viral" post="assembly (Torres et al., 2007; VerdiÃ¡-BÃ¡guena et al., 2012),"/>
 <result pre="ion channel activity and has result they recovered from the" exact="disease" post="and most survived. This evidence confirmed that ion channel"/>
 <result pre="the mechanism of the E-protein ion channel activity in the" exact="viral" post="assembly is an ongoing debate. This is one of"/>
 <result pre="to investigated which deals with E-protein ion channel activity in" exact="viral" post="production to reduce the mortality rate of diseased human"/>
 <result pre="inhibitors are found to have an optimal pharmaceutical activity against" exact="viral" post="protease through mechanism-based irreversible inhibition. They also evaluated a"/>
 <result pre="et al., 2005), and also exhibited an antiviral activity for" exact="infectious" post="bronchitis virus in an animal model(Xue et al., 2008),"/>
 <result pre="al., 2005), and also exhibited an antiviral activity for infectious" exact="bronchitis" post="virus in an animal model(Xue et al., 2008), it"/>
 <result pre="animal model(Xue et al., 2008), it fights to porcine epidemic" exact="diarrhea" post="virus which causes high mortality in pigs as well"/>
 <result pre="approved drug candidates to test in COVID-19 patients. In a" exact="short" post="time, the response of the scientific community is such"/>
 <result pre="and Hydroxychloroquine, old drugs, have been used to treat malarial," exact="rheumatoid arthritis," post="lupus and sun allergies for more than sixty years."/>
 <result pre="old drugs, have been used to treat malarial, rheumatoid arthritis," exact="lupus" post="and sun allergies for more than sixty years. The"/>
 <result pre="been used to treat malarial, rheumatoid arthritis, lupus and sun" exact="allergies" post="for more than sixty years. The activity of hydroxychloroquine"/>
 <result pre="these two molecules is identical. Chloroquine as an antimalarial and" exact="autoimmune disease" post="drugs has shown a synergistically enhancing effect as antiviral"/>
 <result pre="two molecules is identical. Chloroquine as an antimalarial and autoimmune" exact="disease" post="drugs has shown a synergistically enhancing effect as antiviral"/>
 <result pre="standard care in terms of reduction of exacerbation of pneumonia," exact="viral" post="load and symptoms (Chinese Clinical Trial Registry, n.d.; Gao"/>
 <result pre="infection, daily oral dose significantly reduced in serum level of" exact="viral" post="NS1 protein. Caly et al. (2020) have demonstrated Ivermectin-treatment"/>
 <result pre="Caly et al. (2020) have demonstrated Ivermectin-treatment can reduce âˆ¼5000-fold" exact="viral" post="RNA load compared to the control sample in cell"/>
 <result pre="of four investigational therapies for Ebola virus diseased patients. A" exact="total" post="of 681 patients were registered between November 18, 2018"/>
 <result pre="ZMAP and remdesivir group in reducing mortality for Ebola patients," exact="primary" post="groups have faster rate of viral clearance than later"/>
 <result pre="mortality for Ebola patients, primary groups have faster rate of" exact="viral" post="clearance than later groups. Remdesivir has been promised antiviral"/>
 <result pre="and chloroquine are highly effective in the control of COVID-19" exact="infection" post="in vitro experiments. The first COVID-19 patient, 35-year-old in"/>
 <result pre="He reported that he had no shortness of breath or" exact="chest" post="pain. The important signs, fever, cough, rhinorrhea, fatigue, nausea,"/>
 <result pre="pain. The important signs, fever, cough, rhinorrhea, fatigue, nausea, vomit," exact="diarrhea" post="and abdominal discomport, were in normal condition. He had"/>
 <result pre="trial test using lopinavir-ritonavir antiviral drugs for COVID-19 patients. A" exact="total" post="of 199 patients were enrolled for the test, 99"/>
 <result pre="failed to significantly accelerate clinical improvement, reduce mortality, diminish throat" exact="viral" post="RNA detectability in patients with serious COVID-19. In case"/>
 <result pre="patients with serious COVID-19. In case of the severe COVID-19" exact="adult" post="patients, no benefit was observed with lopinavir-ritonavir treatment in"/>
 <result pre="al., 2015; Retallack et al., 2016). It can prevent severe" exact="respiratory" post="tract infection in the case of viral infected patients"/>
 <result pre="Retallack et al., 2016). It can prevent severe respiratory tract" exact="infection" post="in the case of viral infected patients (Bacharier et"/>
 <result pre="can prevent severe respiratory tract infection in the case of" exact="viral" post="infected patients (Bacharier et al., 2015). Gautret group have"/>
 <result pre="patients (Bacharier et al., 2015). Gautret group have treated successfully" exact="chronic" post="disease patients with long-term hydroxychloroquine medicines with 600â€‰mg per"/>
 <result pre="(Bacharier et al., 2015). Gautret group have treated successfully chronic" exact="disease" post="patients with long-term hydroxychloroquine medicines with 600â€‰mg per day"/>
 <result pre="paper reported (Gautret et al., 2020), they are monitored the" exact="viral" post="load in the COVID-19 patients with and without receiving"/>
 <result pre="receiving drugs for the six days. They have examined a" exact="total" post="of 36 patients, 20 hydroxychloroquine-treated patients and 16 control"/>
 <result pre="real-time RT-PCR demonstrated that in comparison to treatment in the" exact="absence of" post="inhibitor, treatment of Ebselen reduced the amount of COVID-19"/>
 <result pre="they reported the protein in complexed with three drugs are" exact="stable" post="during the simulations. The CPAM (china international exchange and"/>
 <result pre="recombinant human monoclonal antibody is a straightforward path to neutralize" exact="viral" post="load of COVID-19. CR3022 is a coronavirus-specific human monoclonal"/>
 <result pre="the potential to be developed as candidate therapeutics of COVID-19" exact="disease" post="(Tian et al., 2020). Other monoclonal, m396, CR3014 antibodies,"/>
 <result pre="2020). 8. Conclusion Effective antiviral-COVID-19 candidates are essential for reducing" exact="disease" post="severity, viral load and transmission, thus helping to prevent"/>
 <result pre="Conclusion Effective antiviral-COVID-19 candidates are essential for reducing disease severity," exact="viral" post="load and transmission, thus helping to prevent the coronavirus"/>
 <result pre="several drugs against SARS-CoV, MERS-CoV tested in animals, and infected" exact="viral" post="cell in lab and proteins vaccines (Graham et al.,"/>
 <result pre="test in vivo experiments that may be suitable for the" exact="disease" post="patient. Following fundamental knowledge of research is required by"/>
 <result pre="N-protein and single positive RNA strand in order to stop" exact="viral" post="replication and transcription. 7. To characterize mechanical profile and"/>
 <result pre="&amp;amp; MartinezF. D., collab: for the National Heart, Lung, and" exact="Blood" post="Instituteâ€™s AsthmaNet (2015). Early Administration of azithromycin and prevention"/>
 <result pre="AsthmaNet (2015). Early Administration of azithromycin and prevention of severe" exact="lower" post="respiratory tract illnesses in preschool children with a history"/>
 <result pre="(2015). Early Administration of azithromycin and prevention of severe lower" exact="respiratory" post="tract illnesses in preschool children with a history of"/>
 <result pre="illnesses a randomized clinical trial. JAMA - Journal of the" exact="American" post="Medical Association, 314(19), 2034â€&quot;2044. 10.1001/jama.2015.1389626575060 BadenL. R., &amp;amp; RubinE."/>
 <result pre="collab: Centers for Desease Control and Prevention (2005). Centers for" exact="Disease" post="Control and Prevention. Frequently asked questions about SARS.https://www.cdc.gov/sars/about/faq.html. collab:"/>
 <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studies. BioScience Trends, 14(1), 72â€&quot;73. 10.5582/bst.2020.0104732074550 GautretP.,"/>
 <result pre="In silico approaches to detect inhibitors of the human severe" exact="acute" post="respiratory syndrome coronavirus envelope protein ion channel. Journal of"/>
 <result pre="silico approaches to detect inhibitors of the human severe acute" exact="respiratory" post="syndrome coronavirus envelope protein ion channel. Journal of Biomolecular"/>
 <result pre="approaches to detect inhibitors of the human severe acute respiratory" exact="syndrome" post="coronavirus envelope protein ion channel. Journal of Biomolecular Structure"/>
 <result pre="the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected" exact="pneumonia" post="(standard version). Military Medical Research, 7(1), 1â€&quot;23. 10.1186/s40779-020-0233-631928528 JinZ.,"/>
 <result pre="modified tool for initial detection and management of middle east" exact="respiratory" post="syndrome patients in the emergency department. Western Journal of"/>
 <result pre="tool for initial detection and management of middle east respiratory" exact="syndrome" post="patients in the emergency department. Western Journal of Emergency"/>
 <result pre="de GrootR. J. (2005). Luxury at a Cost? Recombinant mouse" exact="hepatitis" post="viruses expressing the accessory hemagglutinin esterase protein display reduced"/>
 <result pre="(2015). Evaluation of Ebola virus inhibitors for drug repurposing. ACS" exact="Infectious" post="Diseases, 1(7), 317â€&quot;326. 10.1021/acsinfecdis.5b0003027622822 Mair-JenkinsJ., Saavedra-CamposM., BaillieJ. K., ClearyP.,"/>
 <result pre="convalescent plasma and hyperimmune immunoglobulin for the treatment of severe" exact="acute" post="respiratory infections of viral etiology: A systematic review and"/>
 <result pre="plasma and hyperimmune immunoglobulin for the treatment of severe acute" exact="respiratory" post="infections of viral etiology: A systematic review and exploratory"/>
 <result pre="and hyperimmune immunoglobulin for the treatment of severe acute respiratory" exact="infections" post="of viral etiology: A systematic review and exploratory meta-analysis."/>
 <result pre="immunoglobulin for the treatment of severe acute respiratory infections of" exact="viral" post="etiology: A systematic review and exploratory meta-analysis. Journal of"/>
 <result pre="viral etiology: A systematic review and exploratory meta-analysis. Journal of" exact="Infectious" post="Diseases, 211(1), 80â€&quot;90. 10.1093/infdis/jiu39625030060 MastersP. S. (2006). The molecular"/>
 <result pre="Writing Group (2019). A randomized, controlled trial of Ebola virus" exact="disease" post="therapeutics. New England Journal of Medicine, 381, 2293â€&quot;2303. 10.1056/NEJMoa191099331774950"/>
 <result pre="A., Fernandez-DelgadoR., CastaÃ±o-RodriguezC., AlcarazA., TorresJ., AguilellaV. M., &amp;amp; EnjuanesL. (2014)." exact="Severe" post="Acute Respiratory Syndrome Coronavirus Envelope Protein Ion Channel Activity"/>
 <result pre="Fernandez-DelgadoR., CastaÃ±o-RodriguezC., AlcarazA., TorresJ., AguilellaV. M., &amp;amp; EnjuanesL. (2014). Severe" exact="Acute" post="Respiratory Syndrome Coronavirus Envelope Protein Ion Channel Activity Promotes"/>
 <result pre="CastaÃ±o-RodriguezC., AlcarazA., TorresJ., AguilellaV. M., &amp;amp; EnjuanesL. (2014). Severe Acute" exact="Respiratory" post="Syndrome Coronavirus Envelope Protein Ion Channel Activity Promotes Virus"/>
 <result pre="AlcarazA., TorresJ., AguilellaV. M., &amp;amp; EnjuanesL. (2014). Severe Acute Respiratory" exact="Syndrome" post="Coronavirus Envelope Protein Ion Channel Activity Promotes Virus Fitness"/>
 <result pre="M., &amp;amp; EnjuanesL. (2014). Severe Acute Respiratory Syndrome Coronavirus Envelope" exact="Protein" post="Ion Channel Activity Promotes Virus Fitness and Pathogenesis. PLoS"/>
 <result pre="NamasivayamV., HayashiY., &amp;amp; JungS. H. (2016). An overview of severe" exact="acute" post="respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: Peptidomimetics and small"/>
 <result pre="HayashiY., &amp;amp; JungS. H. (2016). An overview of severe acute" exact="respiratory" post="syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: Peptidomimetics and small molecule"/>
 <result pre="an â€œAchillesâ€™â€™ heelâ€�: Current effective inhibitor targeting a 3C-like protease." exact="Protein" post="&amp;amp; Cell, 4(4), 248â€&quot;250. 10.1007/s13238-013-2841-323549610 RetallackH., Di LulloE., AriasC.,"/>
 <result pre="L. (2016). Zika virus cell tropism in the developing human" exact="brain" post="and inhibition by azithromycin. Proceedings of the National Academy"/>
 <result pre="New insights into the antiviral effects of chloroquine. The Lancet" exact="Infectious" post="Diseases, 6(2), 67â€&quot;69. 10.1016/S1473-3099(06)70361-916439323 SchoemanD., &amp;amp; FieldingB. C. (2019)."/>
 <result pre="L., &amp;amp; BatesP. (2005). Inhibitors of cathepsin L prevent severe" exact="acute" post="respiratory syndrome coronavirus entry. Proceedings of the National Academy"/>
 <result pre="&amp;amp; BatesP. (2005). Inhibitors of cathepsin L prevent severe acute" exact="respiratory" post="syndrome coronavirus entry. Proceedings of the National Academy of"/>
 <result pre="BatesP. (2005). Inhibitors of cathepsin L prevent severe acute respiratory" exact="syndrome" post="coronavirus entry. Proceedings of the National Academy of Sciences,"/>
 <result pre="and characterization of a native, oligomeric form of recombinant severe" exact="acute" post="respiratory syndrome coronavirus spike glycoprotein. Journal of Virology, 78(19),"/>
 <result pre="characterization of a native, oligomeric form of recombinant severe acute" exact="respiratory" post="syndrome coronavirus spike glycoprotein. Journal of Virology, 78(19), 10328â€&quot;10335."/>
 <result pre="of a native, oligomeric form of recombinant severe acute respiratory" exact="syndrome" post="coronavirus spike glycoprotein. Journal of Virology, 78(19), 10328â€&quot;10335. 10.1128/JVI.78.19.10328-10335.200415367599"/>
 <result pre="by a lysine-flanked transmembrane domain of SARS coronavirus envelope protein." exact="Protein" post="Science, 16(9), 2065â€&quot;2071. 10.1110/ps.06273000717766393 Van HemertM. J., Van Den"/>
 <result pre="T. (2005). Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spread. Virology Journal, 2(1), 69â€&quot;10. 10.1186/1743-422X-2-6916115318 WallsA. C.,"/>
 <result pre="Michael acceptor-based peptidomimetic inhibitor of main protease from porcine epidemic" exact="diarrhea" post="virus. Journal of Medicinal Chemistry, 60(7), 3212â€&quot;3216. 10.1021/acs.jmedchem.7b0010328287727 WangQ.,"/>
 <result pre="YuJ., LiangM., &amp;amp; LiD. (2010). Interactions of SARS Coronavirus Nucleocapsid" exact="Protein" post="with the host cell proteasome subunit p42. Virology Journal,"/>
 <result pre="330(1), 322â€&quot;331. 10.1016/j.virol.2004.09.03315527857 collab: World Health Organization (2019). Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV). https://www.who.int/emergencies/mers-cov/en. WrappD., WangN., CorbettK. S., GoldsmithJ."/>
 <result pre="322â€&quot;331. 10.1016/j.virol.2004.09.03315527857 collab: World Health Organization (2019). Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV). https://www.who.int/emergencies/mers-cov/en. WrappD., WangN., CorbettK. S., GoldsmithJ. A.,"/>
 <result pre="C., &amp;amp; ZhangY.-Z. (2020). A new coronavirus associated with human" exact="respiratory" post="disease in China. Nature, 579(7798), 265â€&quot;269. 10.1038/s41586-020-2008-332015508 XueX., YuH.,"/>
 <result pre="&amp;amp; ZhangY.-Z. (2020). A new coronavirus associated with human respiratory" exact="disease" post="in China. Nature, 579(7798), 265â€&quot;269. 10.1038/s41586-020-2008-332015508 XueX., YuH., YangH.,"/>
 <result pre="JiangC. (2013). Anti-malaria drug chloroquine is highly effective in treating" exact="avian influenza" post="A H5N1 virus infection in an animal model. Cell"/>
 <result pre="chloroquine is highly effective in treating avian influenza A H5N1" exact="virus infection" post="in an animal model. Cell Research, 23(2), 300â€&quot;302. 10.1038/cr.2012.16523208422"/>
 <result pre="is highly effective in treating avian influenza A H5N1 virus" exact="infection" post="in an animal model. Cell Research, 23(2), 300â€&quot;302. 10.1038/cr.2012.16523208422"/>
 <result pre="BartlamM., HilgenfeldR., &amp;amp; RaoZ. (2003). The crystal structures of severe" exact="acute" post="respiratory syndrome virus main protease and its complex with"/>
 <result pre="HilgenfeldR., &amp;amp; RaoZ. (2003). The crystal structures of severe acute" exact="respiratory" post="syndrome virus main protease and its complex with an"/>
 <result pre="&amp;amp; RaoZ. (2003). The crystal structures of severe acute respiratory" exact="syndrome" post="virus main protease and its complex with an inhibitor."/>
 <result pre="RaoZ. (2008). Structure of the main protease from a Global" exact="Infectious" post="Human Coronavirus, HCoV-HKU1. Journal of Virology, 82(17), 8647â€&quot;8655. 10.1128/JVI.00298-0818562531"/>
 <result pre="GuoH., JiangR.-D., LiuM.-Q., ChenY., ShenX.-R., WangX., â€¦ ShiZ.-L. (2020). A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
</results>
